Brief: Gain Therapeutics Announces Initiation Of MAD Part Of Phase 1 Clinical Trial Of Gt-02287
27/02/2024 19:01
Feb 27 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS ANNOUNCES THE INITIATION OF THE MULTIPLE
ASCENDING DOSE (MAD) PART OF THE PHASE 1 CLINICAL TRIAL OF
GT-02287, A NOVEL GCASE-TARGETING SMALL MOLECULE THERAPY FOR
GBA1 PARKINSON’S DISEASE
* GAIN THERAPEUTICS INC - EXPECT TO COMPLETE MAD PART OF
PHASE 1
CLINICAL TRIAL IN Q2
Source text for Eikon: ID:nGNX30N4gr
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall